Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor γ-chain signaling and inhibited by cyclosporin A

被引:49
作者
Chklovskaia, E
Nissen, C
Landmann, L
Rahner, C
Pfister, O
Wodnar-Filipowicz, A
机构
[1] Univ Basel Hosp, Res Dept, CH-4031 Basel, Switzerland
[2] Univ Basel, Inst Anat, CH-4056 Basel, Switzerland
关键词
D O I
10.1182/blood.V97.4.1027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The flt3 ligand (FL) is a growth and differentiation factor for primitive hematopoietic precursors, dendritic cells, and natural killer cells, Human T lymphocytes express FL constitutively, but the cytokine is retained intracellularly within the Golgi complex. FL is mobilized from the cytoplasmic stores and its serum levels are massively increased during the period of bone marrow aplasia after stem cell transplantation (SCT), Signals that trigger the release of FL by T cells remain unknown, This study shows that interleukin (IL)-2, IL-4, IL-7, and IL-15, acting through a common receptor gamma chain (gammac), but not cytokines interacting with other receptor families, are efficient inducers of cell surface expression of membrane-bound FL (mFL) and secretion of soluble FL (sFL) by human peripheral blood T lymphocytes. The gammac-mediated signaling up-regulated FL in a T-cell receptor-independent manner. IL-2 and IL-7 stimulated both FL messenger RNA (mRNA) expression and translocation of FL protein to the cell surface. Cyclosporin A (CsA) inhibited gammac-mediated trafficking of FL at the level of transition from the Golgi to the trans-Golgi network, Accordingly, serum levels of sFL and expression of mFL by T cells of CsA-treated recipients of stem cell allografts were reduced approximately 2-fold (P < .01) compared to patients receiving autologous grafts. The conclusion is that FL expression is controlled by <gamma>c receptor signaling and that CsA interferes with FL release by T cells. The link between gammac-dependent T-cell activation and FL expression might be important for T-cell effector functions in graft acceptance and antitumor immunity after SCT. (C) 2001 by The American Society of Hematology.
引用
收藏
页码:1027 / 1034
页数:8
相关论文
共 63 条
  • [31] PLASMA/SERUM LEVELS OF FLT3 LIGAND ARE LOW IN NORMAL INDIVIDUALS AND HIGHLY ELEVATED IN PATIENTS WITH FANCONI-ANEMIA AND ACQUIRED APLASTIC-ANEMIA
    LYMAN, SD
    SEABERG, M
    HANNA, R
    ZAPPONE, J
    BRASEL, K
    ABKOWITZ, JL
    PRCHAL, JT
    SCHULTZ, JC
    SHAHIDI, NT
    [J]. BLOOD, 1995, 86 (11) : 4091 - 4096
  • [32] Flt3 ligand induces tumor regression and antitumor immune responses in vivo
    Lynch, DH
    Andreasen, A
    Maraskovsky, E
    Whitmore, J
    Miller, RE
    Schuh, JCL
    [J]. NATURE MEDICINE, 1997, 3 (06) : 625 - 631
  • [33] Multiple γc-dependent cytokines regulate T-cell development
    Malek, TR
    Porter, BO
    He, YW
    [J]. IMMUNOLOGY TODAY, 1999, 20 (02): : 71 - 76
  • [34] Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
    Maraskovsky, E
    Brasel, K
    Teepe, M
    Roux, ER
    Lyman, SD
    Shortman, K
    McKenna, HJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (05) : 1953 - 1962
  • [35] MARTIN PJ, 1985, BLOOD, V66, P664
  • [36] Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand
    McClanahan, T
    Culpepper, J
    Campbell, D
    Wagner, J
    FranzBacon, K
    Mattson, J
    Tsai, S
    Luh, J
    Guimaraes, MJ
    Mattei, MG
    Rosnet, O
    Birnbaum, D
    Hannum, CH
    [J]. BLOOD, 1996, 88 (09) : 3371 - 3382
  • [37] Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells
    McKenna, HJ
    Stocking, KL
    Miller, RE
    Brasel, K
    De Smedt, T
    Maraskovsky, E
    Maliszewski, CR
    Lynch, DH
    Smith, J
    Pulendran, B
    Roux, ER
    Teepe, M
    Lyman, SD
    Peschon, JJ
    [J]. BLOOD, 2000, 95 (11) : 3489 - 3497
  • [38] IDENTITY OF IMMUNOSUPPRESSANT FR-900520 WITH ASCOMYCIN
    MORISAKI, M
    ARAI, T
    [J]. JOURNAL OF ANTIBIOTICS, 1992, 45 (01) : 126 - 128
  • [39] MOSMANN TR, 1986, J IMMUNOL, V136, P2348
  • [40] B-CELL PRECURSOR GROWTH-PROMOTING ACTIVITY - PURIFICATION AND CHARACTERIZATION OF A GROWTH-FACTOR ACTIVE ON LYMPHOCYTE PRECURSORS
    NAMEN, AE
    SCHMIERER, AE
    MARCH, CJ
    OVERELL, RW
    PARK, LS
    URDAL, DL
    MOCHIZUKI, DY
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (03) : 988 - 1002